No Data
No Data
NKGen Biotech Presents Data From Phase 1/2a Trial of Troculeucel
NKGen Biotech Delays Annual Report Filing
Express News | NKGen Biotech To Present On Potential Of Troculeucel For The Treatment Of Neurodegenerative Diseases At The 13th Annual Alzheimer's & Parkinson's Drug Development Summit March 18–20, 2025
NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer's & Parkinson's Drug Development Summit
NKGen to Transfer Listing to OTC Markets; Shares Drop
NKGen Biotech, Inc. to Transition From the Nasdaq Global Market to OTC Markets; Reverse Stock Split Will Not Be Implemented